Terence G Hamill

This inventor holds 7 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignees: Merck + Co., Inc., Merck Sharp + Dohme Corp., Banyu Pharmaceutical Co. Ltd. Active years: 2001-2014.

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 57.1

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 44(Granted Patents)

Location History:

Landsdale, PA (US) (2010)
Lansdale, PA (US) (2001 - 2014)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

1 out of 237

Banyu Pharmaceutical Co. Ltd

patents

where one patent can have more than one assignee

Years Active: 2001-2014

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8664253 - Imidazole derivatives useful as modulators of FAAH and as FAAH imaging agents (2014-03-04),

2. 7834031 - Radiolabeled glycine transporter inhibitors (2010-11-16),

3. 7754188 - Radiolabeled cannabinoid-1 receptor modulators (2010-07-13),

4. 7354935 - Radiolabeled neurokinin-1 receptor antagonists (2008-04-08),

5. 6939966 - Radiolabeled neuropeptide Y Y5 receptor antagonists (2005-09-06),

6. 6458935 - Radiolabeled farnesyl-protein transferase inhibitors (2002-10-01),

7. 6241964 - F-18 radiolabeled neurokinin-1 receptor antagonists (2001-06-05),

Title: Terence G Hamill: Innovator in Pharmaceutical Chemistry

Introduction

Terence G Hamill is a notable inventor based in Lansdale, PA (US), recognized for his contributions to pharmaceutical chemistry. He holds a total of 7 patents, showcasing his innovative approach to addressing various medical conditions through chemical compounds.

Latest Patents

One of his latest patents is focused on imidazole derivatives that serve as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. This invention is significant as it includes pharmaceutical formulations that utilize these compounds to treat disorders such as osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, fibromyalgia, acute pain, migraine, sleep disorders, Alzheimer’s Disease, and Parkinson's Disease. Another important patent involves radiolabeled glycine transporter inhibitors, which are essential for the labeling and diagnostic imaging of glycine transporters in mammals.

Career Highlights

Throughout his career, Terence has worked with prominent companies such as Merck & Company, Inc. and Merck Sharp & Dohme Corporation. His work in these organizations has contributed significantly to advancements in pharmaceutical research and development.

Collaborations

He has collaborated with notable colleagues, including H Donald Burns and Raymond E Gibson, further enhancing the impact of his inventions in the field.

Conclusion

Terence G Hamill's innovative work in pharmaceutical chemistry has led to significant advancements in the treatment of various medical conditions. His contributions through patents and collaborations continue to influence the industry positively.